Piper Sandler维持对Edwards Lifesciences的增持评级，理由是尽管即将公布试验数据，但增长潜力强劲，且TAVR处于领先地位。 Piper Sandler maintains Overweight rating on Edwards Lifesciences, citing strong growth potential and TAVR leadership despite upcoming trial data.

Piper Sandler对Edwards Lifesciences保持超重评分, 指出尽管合作伙伴三号实验的7年后续数据即将出现, 但长期增长潜力仍很强。 Piper Sandler keeps an Overweight rating on Edwards Lifesciences, citing strong long-term growth potential despite upcoming 7-year follow-up data from the PARTNER 3 trial. 该公司仍然相信Edwards TAVR技术的耐久性和临床效益,特别是支持其市场领导力的低风险病人。 The firm remains confident in the durability and clinical benefits of Edwards’ TAVR technology, especially in low-risk patients, which supports its market leadership. 虽然数据可能会影响投资者的情绪,但Piper Sandler强调该公司强劲的产品管道、全球扩张和持续执行是未来在结构性心脏病市场上取得成功的关键驱动力。 While the data could impact investor sentiment, Piper Sandler highlights the company’s robust product pipeline, global expansion, and consistent execution as key drivers of future success in the structural heart disease market.